Otolaryngology-Head and Neck Surgery, Tripler Army Medical Center, Honolulu, HI, USA.
Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Mass General Brigham, Boston, MA, USA.
J Robot Surg. 2024 Nov 7;18(1):398. doi: 10.1007/s11701-024-02155-7.
Transoral robotic surgery (TORS) has become a common surgical approach for the treatment of both benign and malignant conditions of the oropharynx. While the newer da Vinci Xi platform has largely replaced the previous Si model in many institutions, the reported outcomes with this system in head and neck surgery are limited. We report the feasibility of using the da Vinci Xi platform for managing oropharyngeal cancer and obstructive sleep apnea in a low-volume center. This retrospective review from a consecutive case series includes demographic, procedural, and outcome data from all patients who underwent TORS using the da Vinci Xi platform at a single institution over a 5-year period from 2019 to 2023. Thirty-five patients (19 males and 16 females) underwent TORS for a variety of indications. No patients were excluded from the study. There were no mortalities, readmissions, or severe complications directly related to the primary surgery. Our case series demonstrates that TORS is feasible with the da Vinci Xi system even in low-volume centers and supports the existing data suggesting that the Xi platform has an acceptable safety profile.
经口机器人手术(TORS)已成为治疗口咽良性和恶性疾病的常用手术方法。虽然在许多机构中,更新的达芬奇 Xi 平台已在很大程度上取代了之前的 Si 模型,但该系统在头颈部手术中的报道结果有限。我们报告了在低容量中心使用达芬奇 Xi 平台管理口咽癌和阻塞性睡眠呼吸暂停的可行性。这项回顾性连续病例系列研究包括 2019 年至 2023 年期间在单一机构中使用达芬奇 Xi 平台进行 TORS 的所有患者的人口统计学、程序和结果数据。35 名患者(19 名男性和 16 名女性)因各种适应症接受了 TORS。研究中没有排除任何患者。没有与主要手术直接相关的死亡、再入院或严重并发症。我们的病例系列表明,即使在低容量中心,达芬奇 Xi 系统也可以进行 TORS,这支持了现有的数据,表明 Xi 平台具有可接受的安全性。